Precision for Medicine

Get more clinical research insight with our FREE newsletter sign me up

ABOUT PRECISION FOR MEDICINE

Precision for Medicine is an industry-leading global precision medicine clinical research organization and a leader in complex clinical development. Our clients benefit from advanced technologies and new approaches that compress timelines, gain efficiencies, and increase the probability of approval. Under one global roof, Precision has integrated sophisticated biomarker capabilities and laboratory expertise, worldwide CRO services, data intelligence solutions, and more. With 6 specialty labs and 3,500+ professionals worldwide, we help clients accelerate life-changing treatments and propel medicine forward.

FEATURED PRODUCTS

Metavate: Automated, Metadata-Driven, Data Transformation

Embedded, flexible clinical services model that scales sponsor capacity, standardizes quality delivery, and accelerates clinical development while sponsors retain strategic and operational control.
Why Multi-Omic Insights Demand A Multi-Omic Strategy

Gene therapy development faces complex scientific and regulatory challenges. Success requires optimized vectors, robust preclinical studies, biomarker strategies, and coordinated FDA engagement.
Smarter Oversight, Earlier Action

When risk-based oversight is reduced to a compliance checkbox, critical signals can be missed and escalate into systemic issues.
Custom Biospecimens Collections

With an in-house donor center and database of donors, along with an established network of hospitals and care centers, Precision can source virtually any disease type or sample type biospecimens needed for your project.
IVD And CDx: Comprehensive Services From Research To Regulatory

Navigating diagnostic development requires deep scientific expertise and adept regulatory support. Comprehensive solutions offer biospecimens, biomarker development, clinical trial support, and global regulatory services.
IVD Regulatory Consulting Services

With effective IVD regulatory consulting from an expert team, sponsors can transform challenges into competitive advantages and bring high-quality diagnostics to market more efficiently.
Strategic Scalability: Functional Service Provider Solutions

What services are available to help you ensure continuous functional coverage, enhancing business continuity, operational efficiency, and risk mitigation?
Empowering Clinical Programs With Centers Of Excellence

The right site network can help transform clinical trial execution by aligning top-tier investigators and centers of excellence with high-quality clinical studies, driving faster patient access.
Life-Changing Therapies Without A Lifetime Of Development

Learn about this integrated suite of services that spans global CRO capabilities, central laboratory services, and IVD & CDx regulatory development consulting.
High-Content Flow Cytometry

Flow cytometry is a foundational tool in modern drug development, and its application in receptor occupancy assays has become essential for evaluating therapeutic engagement with disease targets.
Precision Kitting: Every Sample Matters, Every Detail Counts

Precision starts at collection. The integrity of trial data depends on accurate, compliant, and traceable sample handling, but standard kitting isn’t built for the demands of biomarker-driven research.
Overview Of Precision For Medicine's Pathology Services

Explore an integrated approach to support biomarker-driven development programs that accelerates your development timelines, helping you achieve your research goals faster and more effectively.
Translational And Biomarker Sciences: Enabling Breakthroughs

Learn about expert services specializing in precision medicine and biomarker-driven contract and clinical research that can assist you through translational solutions.
Combining Automation And Human Expertise For Custom Kitting

While automated inventory management systems play a crucial role in tracking samples, kit availability, and supply levels human involvement is still important to the adaptability of a clinical trial.

WEBINARS AND VIDEOS

55:59

Breaking Barriers With PCR

Breaking Barriers With PCR: Innovative Solutions For Clinical Trial Success

58:41

Beyond the data deluge image

Beyond The Data Deluge: Immune Profiling In Early Immuno-Oncology Trials

4:15

GettyImages-1551861554-FDA

The 3 FDA Oncology Approvals That Will Have The Biggest Impact In 2025

4:11

FDA Headquarters-GettyImages-1286971245

The FDA's New Guidance May Be Shaking Up Biotech

More Webinars and Videos

CONTACT INFORMATION

Precision for Medicine

2 Bethesda Metro Ctr Ste 850

Bethesda, MD 20814-5398

UNITED STATES

Contact: Nandita Handoo

Request More Information

Visit Our Website

FEATURED ARTICLES

MHRA International Recognition: Fast-Track UK Market Access

MHRA’s IRP accelerates UK approvals via trusted regulators, but faster authorization only translates to access when aligned with NICE evidence needs, pricing policy, and coordinated launch strategy.
Accelerating Milestones And Reducing Regulatory Risk

Modern adaptive Phase 1 oncology trials speed timelines, refine dosing, and meet FDA standards, replacing outdated 3+3 methods to boost efficiency, safety, and regulatory success.
Gene Therapy & CDx: Smarter Development

Gene therapy success depends on optimized vectors, robust trials, biomarker-driven strategies, and coordinated regulatory planning for companion diagnostics and FDA engagement.
Preserving Genomic Data's Living Legacy

Public genomic datasets like TCGA transformed cancer research, guiding assay validation and cohort design. Today, matched biospecimens complete the loop between digital insight and biological confirmation.
Investor Relations, Clinical Operations, And The Future Of Biotech Financing

Discover how integrating clinical execution with investor strategy can strengthen your position in a tougher capital landscape and accelerate your path to market.
Dose Optimization: A Strategic Lever In Oncology Drug Development

Targeted therapies, immunotherapies, antibody–drug conjugates, and other biologics demand a patient-centered strategy that recognizes that higher doses do not always translate to better outcomes.
Lost In Translation: Turning Multi-Omic Chaos Into Clinical Clarity

Uncover how this integrated, science-focused approach helps sponsors navigate biological complexity, streamline timelines, and make data-driven decisions across a collection of therapy programs.
The Immune System's Secret Language: Unlocking Cellular Communication

The rising rate of autoimmune conditions requires better ways to monitor cellular activity. See how profiling immune cells by their DNA signatures enables real-time therapeutic insight and prediction.
Prospecting Biospecimen Collections To Power Precision Medicine

High-quality biospecimens are the foundation of precision medicine success. Learn the five crucial steps—from planning to compliance—for a prospective biospecimen collection that is scientifically robust and accelerates your research.
Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)

The Bayesian Logistic Regression Model (BLRM) is redefining Phase I clinical trial design by bringing flexibility, precision, and patient-centered safety into early drug development.
Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)

The benefits are clear: CRM accelerates dose finding, reduces patient exposure to unsafe doses, and improves trial efficiency.
Effect Of Etrasimod On Immune Cell Subsets In Colonic Tissue

Etrasimod selectively modulates S1P receptors to reduce inflammation and immune cell trafficking to the gut, showing promise in treating moderate to severe ulcerative colitis.
Phase 1 Clinical Trial Designs Explained: BOIN, CRM, BLRM, And Modern Adaptive Strategies

As precision medicine evolves, trial designs must increasingly accommodate personalized therapies, adaptive strategies, and AI-driven modeling.
Conducting Autologous Cell Therapy Research With Zero Sample Loss

Autologous cell therapy trials require precision at every stage—and this biomarker-specific solid tumor study exemplified the challenge.
FDA Draft Guidance On Overall Survival in Oncology Trials

Historically regarded as the gold standard efficacy endpoint, Overall Survival (OS) in oncology trials is now positioned not only as a measure of therapeutic benefit but also as a critical safety endpoint.
How AI & Biomarkers Are Reshaping The Next Frontier In Drug Development

Learn more about the importance of biomarker-driven drug development and the integration of laboratory science, clinical expertise, and regulatory strategy to accelerate targeted therapy development.
Phase 1 Clinical Trial Designs And Strategies

With tailored guidance, sponsors can align their modern model-based and model-assisted design choices to program goals, accelerating progress while safeguarding patients.
Rescue Studies

Clinical trials frequently encounter delays, and rescue studies have become vital to address this challenge, especially in complex therapeutic areas.
Understanding Immunogenicity In AAV Gene Therapy

As adeno-associated virus-based gene therapies progress toward clinical use, effectively managing immunogenicity risk is critical to patient selection, therapeutic durability, and regulatory success.
Rarefied Thinking In Rare Disease Research

This integrated approach to rare disease research combines clinical, operational, laboratory, regulatory, and data management expertise to maximize insights from every patient interaction.

CASE STUDIES

Developing And Validating Clinical Receptor Occupancy Pharmacodynamic Biomarker Assays

Receptor occupancy (RO) assays assess drug-target engagement and support PK/PD modeling. Accurate RO requires customized assays using stabilized blood to monitor CD6 modulation in autoimmune therapy.
Rapid Startup Phase 1 Cardiomyopathy CRISPR Gene Therapy

Hereditary transthyretin amyloidosis (ATTRv) is very rare, prompting a Phase 1 trial of in vivo CRISPR/Cas9 gene editing to reduce mutant protein and stop cardiomyopathy progression.
Use Of Epiontis ID In A Phase 2 Psoriasis Trial

Mirikizumab’s Phase 2 trial explores IL-23 inhibition in psoriasis, measuring immune cell changes to assess its potential for long-term disease control and flare-up prevention.
Optimizing Kitting For Cell Therapy Trials In Pediatric Oncology

Precision for Medicine’s Kitting team played a crucial role in overcoming this challenges of a Phase I multicenter pediatric cell therapy trial targeting relapsed or refractory solid tumors.

More Case Studies